{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:01:13Z","timestamp":1785254473172,"version":"3.55.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Federally sponsored cancer clinical trials (FS-CCTs) address research questions often overlooked by industry (eg, pharmaceutical or biotechnology companies), such as treatment combinations, rare cancers, within-class comparisons, and de-escalation strategies. However, drug costs in these trials have not been comprehensively quantified. Federal agencies typically support trial infrastructure but not drugs, necessitating cosponsorship or in-kind donations from pharmaceutical companies. These arrangements often involve complex contractual processes that may delay trial initiation. Quantifying drug-related costs is important for informing policy and optimizing federal support for cancer research.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the direct purchase costs of drugs in FS-CCTs and examine cost patterns across sponsor types and therapeutic classes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This systematic review included a search of the ClinicalTrials.gov registry using a structured query to identify all US-based cancer treatment trials initiated between January 1, 2017, and December 31, 2023, that involved pharmaceutical or biological interventions and received federal sponsorship. Analyses were conducted between June 1 and September 20, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Drug or biological interventions in FS-CCTs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Wholesale acquisition cost\u2013based trial-level total and per-patient drug costs. Between-group comparisons used Mann-Whitney and Kruskal-Wallis tests for 2- and multiple-group comparisons, respectively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1378 US FS-CCTs with 140 066 participants were included in the analysis. The estimated median trial-level drug costs were $7.58 million (IQR, $2.11-$19.88 million), with substantially higher median costs for phase 3 trials ($58.92 million [IQR, $12.25-$127.17 million]) vs early phase trials ($6.90 million [IQR, $2.01-$17.70 million]) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and for immunotherapies ($9.25 million [IQR, $3.12-$23.22 million]), targeted therapies ($6.60 million [IQR, $2.22-$18.06 million]), and combined immunotherapy and targeted therapy ($15.08 million [IQR, $6.30-$34.83 million]) compared with chemotherapy ($0.43 million [IQR, $0.11-$2.87 million]) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Experimental agents accounted for\u2009approximately 80% of total drug costs. The median per-patient drug costs were higher in trials that were solely federally funded ($196 764 [IQR, $83 516-$414 514]) vs cosponsored trials ($149 879 [IQR, $35 329-$390 142]) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Among 221 comparative phases 2 to 3 trials, the median experimental arm costs ($12.91 million [IQR, $3.37-$46.96 million]) were 5-fold higher than in control arms ($2.05 million [IQR, $0.16-$11.31 million]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review of FS-CCTs, drug costs were substantial, particularly in late-stage trials and those examining immunotherapies and targeted agents. High costs routinely required federally sponsored groups to seek industry support, which may have limited independence and constrained new treatment discovery. Policy innovations are needed to reduce trial drug cost burden and enable FS-CCT researchers to conduct scientifically and clinically relevant trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.25814","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:30:20Z","timestamp":1785252620000},"page":"e2625814","source":"Crossref","is-referenced-by-count":0,"title":["Drug Costs in Federally Sponsored Cancer Clinical Trials"],"prefix":"10.1001","volume":"9","author":[{"given":"Hong","family":"Xiao","sequence":"first","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Bertagnolli","sequence":"additional","affiliation":[{"name":"Harvard Kennedy School, Harvard University, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Ashley","family":"Threlkel","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chansky","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"16","key":"zoi260713r2","doi-asserted-by":"publisher","first-page":"11095","DOI":"10.1200\/JCO.2025.43.16_suppl.11095","article-title":"The studies industry neglects: characteristics of cancer clinical trials conducted by federal versus industry sponsors.","volume":"43","author":"Unger","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi260713r3","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.18632\/oncotarget.24589","article-title":"Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer.","volume":"9","author":"Tibau","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"zoi260713r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.10593","article-title":"Association of National Cancer Institute\u2013sponsored clinical trial network group studies with guideline care and new drug indications.","volume":"2","author":"Unger","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260713r5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/jnci\/djz234","article-title":"Evolution of cancer care delivery research in the NCI Community Oncology Research Program.","volume":"112","author":"Geiger","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"zoi260713r6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.22.01826","article-title":"Population, clinical, and scientific impact of National Cancer Institute\u2019s national clinical trials network treatment studies.","volume":"41","author":"Unger","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260713r7","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa034","article-title":"Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies.","volume":"4","author":"Unger","year":"2020","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"7","key":"zoi260713r8","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1257\/aer.20131176","article-title":"Do firms underinvest in long-term research? evidence from cancer clinical trials.","volume":"105","author":"Budish","year":"2015","journal-title":"Am Econ Rev"},{"issue":"23","key":"zoi260713r9","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1002\/cncr.33209","article-title":"What happened to the US cancer cooperative groups? a status update ten years after the Institute of Medicine report.","volume":"126","author":"Bertagnolli","year":"2020","journal-title":"Cancer"},{"issue":"33","key":"zoi260713r10","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1200\/JCO.24.00843","article-title":"Patient enrollment to industry-sponsored versus federally-sponsored cancer clinical trials.","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260713r11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology.","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"28","key":"zoi260713r12","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1200\/JCO.2006.06.7819","article-title":"Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.","volume":"24","author":"Dilts","year":"2006","journal-title":"J Clin Oncol"},{"issue":"33","key":"zoi260713r14","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1200\/JCO-24-01484","article-title":"Bridging the gap in cancer clinical trial funding.","volume":"42","author":"Abdou","year":"2024","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi260713r15","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1200\/JCO.2003.08.156","article-title":"The costs of conducting clinical research.","volume":"21","author":"Emanuel","year":"2003","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi260713r16","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1200\/JCO.2005.05.0104","article-title":"Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.","volume":"24","author":"Dilts","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi260713r17","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1002\/cncr.33210","article-title":"The National Clinical Trials Network and the cooperative groups: the road not taken.","volume":"126","author":"Schilsky","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"zoi260713r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0626","article-title":"Estimating rebates and other discounts received by Medicare Part D.","volume":"2","author":"Feldman","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"11","key":"zoi260713r20","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1200\/JCO.22.02628","article-title":"The National Clinical Trials Network: a valuable and undervalued resource.","volume":"41","author":"Burris","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi260713r21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamainternmed.2025.2892","article-title":"Oncology \u201cme-too\u201d drugs compared with original drugs in randomized clinical trials.","volume":"185","author":"Olivier","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"33","key":"zoi260713r22","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement.","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"41","key":"zoi260713r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_100028","article-title":"An Arm and a leg: the rising cost of cancer drugs and impact on access.","volume":"41","author":"Leighl","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"zoi260713r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2026","article-title":"Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe.","volume":"7","author":"Vokinger","year":"2021","journal-title":"JAMA Oncol"},{"key":"zoi260713r26","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00927","article-title":"Ensuring the future of cooperative group cancer clinical trials: a call for comprehensive support and prioritization.","author":"Lieu","year":"2026","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"zoi260713r27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1073\/pnas.1715368115","article-title":"Contribution of NIH funding to new drug approvals 2010-2016.","volume":"115","author":"Galkina Cleary","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"zoi260713r28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1634\/theoncologist.2012-0423","article-title":"Publicly funded clinical trials and the future of cancer care.","volume":"18","author":"Schilsky","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"zoi260713r29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both.","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260713r30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"2","key":"zoi260713r31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/COC.0000000000001054","article-title":"Insurance denial of care for randomized controlled trial-eligible patients: incidence and success rate of peer-to-peer authorization in allowing patients to remain trial-eligible.","volume":"47","author":"McClelland","year":"2024","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"zoi260713r32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JOP.0834601","article-title":"Collaboration between cooperative groups and industry.","volume":"4","author":"Bressler","year":"2008","journal-title":"J Oncol Pract"},{"issue":"11","key":"zoi260713r33","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1200\/JCO.2008.19.9133","article-title":"Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.","volume":"27","author":"Dilts","year":"2009","journal-title":"J Clin Oncol"},{"key":"zoi260713r34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_321475","article-title":"Overcoming barriers to clinical trials cooperation: the Breast International Group example.","volume":"41","author":"Piccart-Gebhart","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"zoi260713r1","volume-title":"A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program","author":"Institute of Medicine (US) Committee on Cancer Clinical Trials and the NCI Cooperative Group Program","year":"2010"},{"key":"zoi260713r13","unstructured":"NCI formulary. National Cancer Institute, Division of Cancer Treatment and Diagnosis. April 24, 2026. Accessed April 24, 2026. https:\/\/dctd.cancer.gov\/drug-discovery-development\/reagents-materials\/formulary"},{"key":"zoi260713r18","unstructured":"Micromedex Red Book. IBM Watson Health. Updated July 7, 2025. Accessed February 25, 2025. https:\/\/www.micromedexsolutions.com\/home\/dispatch\/ssl\/true"},{"key":"zoi260713r25","unstructured":"Promoting value, affordability, and innovation in cancer drug treatment. President\u2019s Cancer Panel. 2018. Accessed November 4, 2025. https:\/\/prescancerpanel.cancer.gov\/reports-meetings\/drug-value-report-2018"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2852138\/xiao_2026_oi_260713_1784645738.71337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:30:26Z","timestamp":1785252626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2852138"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.25814","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}